Evaluation of infliximab as second-line treatment of acute graft versus host disease -validating response on day 7 and 28 as predictors of survival

Several immunosuppressive drugs have been proposed for second-line treatment of steroid-refractory acute graft versus host disease (aGvHD) after allogeneic hematopoietic stem cell transplantation. However, the studies on these drugs are small, retrospective, uncontrolled and use different endpoints....

Descripción completa

Detalles Bibliográficos
Autores principales: Nygaard, Marietta, Andersen, Niels Smedegaard, Moser, Claus Ernst, Olesen, Gitte, Schjødt, Ida Marie, Heilmann, Carsten, Sengeløv, Henrik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7086567/
https://www.ncbi.nlm.nih.gov/pubmed/29391524
http://dx.doi.org/10.1038/s41409-018-0099-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7086567/
https://www.ncbi.nlm.nih.gov/pubmed/29391524
http://dx.doi.org/10.1038/s41409-018-0099-3

Ejemplares similares